Legal status in the United States
Is PT-141 legal?
Read at FDA, DEA and WADAPublished by PepVault
PT-141 (bremelanotide) is FDA-approved (Vyleesi, first in 2019), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.
PT-141 at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Approved (Vyleesi, 2019) |
| Compounding | Component of an approved drug (503A condition) |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named on the list |
FDA approval
Bremelanotide, sold on the street as PT-141, is FDA-approved as Vyleesi, since 2019, for one use in premenopausal women.
Vyleesi (injection)
Approved for low sexual desire that causes marked distress (acquired, generalized hypoactive sexual desire disorder) in premenopausal women; its label says it is not for men or to enhance sexual performance. NDA 210557, first approved June 21, 2019.
- Drugs@FDA: Vyleesi, application 210557, U.S. Food and Drug Administration. Read .
- Vyleesi prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
- Drugs@FDA: Vyleesi, application 210557, U.S. Food and Drug Administration. Read .

Compounding
Bremelanotide is the active ingredient of an FDA-approved drug (Vyleesi). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name bremelanotide.
The source: “Are components of FDA-approved drug products if an applicable USP or NF monograph does not exist”
- Bulk Drug Substances Used in Compounding (content current as of March 26, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
The 2026 Prohibited List doesn’t name bremelanotide, and S0, the class for unapproved substances, doesn’t reach an approved drug.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about PT-141 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is PT-141 FDA approved?
Bremelanotide, sold on the street as PT-141, is FDA-approved as Vyleesi, since 2019, for one use in premenopausal women.
Is PT-141 a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is PT-141 banned in sport?
The 2026 Prohibited List doesn’t name bremelanotide, and S0, the class for unapproved substances, doesn’t reach an approved drug.
What does FDA say about compounding PT-141?
Bremelanotide is the active ingredient of an FDA-approved drug (Vyleesi). FDA’s page on bulk drug substances gives three conditions under section 503A for a substance a pharmacy compounds from, and one of them is being a component of an FDA-approved drug product; the 503A and 503B bulks lists don’t name bremelanotide.